Semaglutide is a 31-residue, acylated analog of human GLP-1 engineered for DPP-4 stability and reversible albumin binding. It selectively activates the GLP-1 receptor, so its evidence base should be read through GLP-1R mechanism, study population, formulation, and endpoint. Apex Laboratory supplies Semaglutide as a research-grade chemical reagent for in-vitro and preclinical research, distinct from the Ozempic, Rybelsus, Wegovy, and Wegovy HD pharmaceutical formulations.
Semaglutide now has an unusually broad evidence and regulatory record. That breadth makes scope discipline more important, not less. Molecular design, receptor mechanism, a named clinical program, an FDA-approved finished product, and a separate research reagent are connected records, but they are not interchangeable records.
This guide checks the U.S. FDA record through March 19, 2026 and the scientific sources through July 24, 2026. The GLP-1 and metabolic research hub owns family-level navigation; this guide owns Semaglutide molecular identity, GLP-1R mechanism, and its evidence map.
- Semaglutide is a 31-residue GLP-1 analog with three design changes that support DPP-4 stability, reversible albumin binding, and single-site acylation.
- It selectively activates GLP-1R; downstream findings remain assay-, tissue-, population-, formulation-, and endpoint-specific.
- SUSTAIN, PIONEER, STEP, SELECT, and ESSENCE/MASH answer different questions and should not be collapsed into one generic efficacy claim.
- The U.S. regulatory record expanded materially in 2025 and 2026, including MASH, tablet, kidney, and Wegovy HD records.
- Same molecule (semaglutide); categorically distinct regulatory frameworks. An Apex reagent is not an approved pharmaceutical.
Semaglutide Molecular Identity and Design
FDA’s current Ozempic description identifies Semaglutide as a human GLP-1 receptor agonist with 94% sequence homology to native human GLP-1. The molecule contains 31 amino-acid residues, has the molecular formula C187H291N45O59, and has a molecular weight of 4113.58 g/mol. Those values correct the molecular formula reported in the earlier version of this guide.
Three design changes organize the molecule’s identity. A position-8 substitution improves stability against DPP-4 cleavage. Lysine 26 carries a hydrophilic spacer and a C18 fatty di-acid that supports reversible albumin binding. A position-34 change ensures that the fatty di-acid attaches at one intended site. Lau and colleagues documented the medicinal-chemistry program that produced this design, while Knudsen and Lau placed it within Novo Nordisk’s liraglutide-to-semaglutide development lineage.[1][2]
Lau and colleagues measured the protraction that design buys: a GLP-1R binding affinity of 0.38 nM, a plasma half-life of 46.1 hours after intravenous dosing in mini-pigs, and a 63.6-hour mean residence time after subcutaneous dosing in the same species.[1] The SUSTAIN-6 report describes the human injectable finished product as having an extended half-life of approximately 1 week.[6]
| Reagent identity field | Value | Source |
|---|---|---|
| CAS Registry Number | 910463-68-2 | Chemical registry identifier for semaglutide |
| Molecular formula | C187H291N45O59 | FDA Ozempic prescribing information [14] |
| Molecular weight | 4113.58 g/mol | FDA Ozempic prescribing information [14] |
| Backbone | 31 residues; [Aib8, Arg34] analog of GLP-1(7-37), acylated at the Lys26 side chain | PMID 26308095 |
| Sequence (3-letter) | His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly | PMID 26308095 substitutions on the GLP-1(7-37) backbone |
The design has two experimentally important consequences: protection from rapid DPP-4 degradation and protraction through albumin binding. Neither consequence erases context. Binding measurements, proteolysis assays, pharmacokinetic observations, and finished-product exposure data are distinct evidence types. A result from one type should not be presented as if it directly establishes all the others.
Selective GLP-1 Receptor Mechanism
Semaglutide selectively binds and activates the GLP-1 receptor, a class B G-protein-coupled receptor. In responsive systems, GLP-1R signals mainly through Gs, adenylyl cyclase, and cyclic AMP. The native GLP-1 literature establishes the glucose-dependent islet logic, while later reviews integrate islet, gastrointestinal, neural, and cardiovascular biology.[3][4] Both are mechanistic syntheses rather than trials, and each reports no single quantitative endpoint of its own; the figures used in this guide come from the primary trial reports cited below.
Mechanism is not one universal endpoint. A receptor-binding experiment asks a different question from a cAMP assay. A beta-cell secretion model adds glucose concentration and cellular competence. Gastric-emptying or central-appetite observations add organ systems and intact-organism variables. Clinical outcomes add formulation, population, comparator, adherence, and follow-up. The phrase “GLP-1R agonist” names a target relationship; it does not make every downstream result transferable.
Receptor selectivity also separates Semaglutide from multi-receptor compounds. Semaglutide is GLP-1R-selective; Tirzepatide is a dual GIPR/GLP-1R agonist; Retatrutide engages GIPR, GLP-1R, and the glucagon receptor. The Semaglutide versus Tirzepatide comparison owns the exact binary analysis, while the modern GLP-1 agonist comparison owns the three-way framework.
Semaglutide Evidence Programs and Landmark Results
Program names help readers keep population and formulation attached to a result. SUSTAIN evaluated injectable Semaglutide in type 2 diabetes; PIONEER evaluated an oral finished formulation in type 2 diabetes; STEP evaluated weight-related outcomes in defined overweight or obesity populations; SELECT tested cardiovascular outcomes in adults with established cardiovascular disease and overweight or obesity but without diabetes; and ESSENCE evaluates MASH and liver-fibrosis outcomes.
| Program | Evidence landmark | Interpretive boundary | Source |
|---|---|---|---|
| SUSTAIN | SUSTAIN 1 randomized 388 treatment-naive adults with type 2 diabetes for 30 weeks: HbA1c fell 1.45 percentage points on 0.5 mg weekly and 1.55 on 1.0 mg weekly, versus 0.02 on placebo.[5] SUSTAIN-6 followed 3,297 adults with type 2 diabetes at high cardiovascular risk for 104 weeks: the primary composite occurred in 6.6% versus 8.9% on placebo (hazard ratio 0.74, 95% CI 0.58 to 0.95).[6] | Injectable finished formulation, named diabetes populations, defined comparators, and trial endpoints. | PMID 28110911; PMID 27633186 |
| PIONEER | PIONEER 1 randomized 703 adults with type 2 diabetes to oral Semaglutide 3, 7 or 14 mg daily for 26 weeks, with placebo-adjusted HbA1c differences of 0.6, 0.9 and 1.1 percentage points.[7] PIONEER 6 followed 3,183 adults with type 2 diabetes at elevated cardiovascular risk for a median 15.9 months: major adverse cardiovascular events occurred in 3.8% versus 4.8% on placebo (hazard ratio 0.79).[8] | The oral tablet record includes formulation-specific absorption technology and cannot be assigned to an injection or reagent. | PMID 31186300; PMID 31185157 |
| STEP | At week 68 on once-weekly 2.4 mg, STEP 1 reported -14.9% versus -2.4% body weight in 1,961 adults without diabetes;[9] STEP 2, -9.6% versus -3.4% in 1,210 adults with type 2 diabetes;[10] STEP 3, -16.0% versus -5.7% in 611 adults also receiving intensive behavioral therapy;[11] and STEP 4, -7.9% with continued treatment versus +6.9% after a switch to placebo in 803 adults who completed a 20-week run-in.[12] | Participant criteria, co-interventions, finished formulation, timepoint, and endpoint remain part of every result. | PMID 33567185; PMID 33667417; PMID 33625476; PMID 33755728 |
| SELECT | SELECT enrolled 17,604 adults with established cardiovascular disease and overweight or obesity, but without diabetes; over a mean 39.8 months the primary cardiovascular composite occurred in 6.5% versus 8.0% on placebo (hazard ratio 0.80, 95% CI 0.72 to 0.90).[13] | The outcome belongs to the SELECT population and pharmaceutical context, not to Semaglutide material in general. | PMID 37952131 |
| ESSENCE / MASH | An interim phase 3 liver-histology analysis supported FDA accelerated approval for a Wegovy injection MASH indication in August 2025. | The 240-week confirmatory clinical-benefit trial remains ongoing; accelerated approval is not a reagent claim. | FDA Wegovy MASH accelerated-approval letter, NDA 215256/S-024 [20] |
Every figure above stays attached to its own trial: a named finished formulation, an enrolled population, a comparator, a fixed observation window, and one prespecified endpoint. None of them describes Semaglutide in the abstract, and none of them describes a research reagent.
Peer-reviewed clinical outcomes establish evidence for the specified study populations and finished pharmaceutical products. They do not establish pharmaceutical manufacturing, sterility, exposure, safety, efficacy, or therapeutic equivalence for an Apex chemical reagent.
U.S. Regulatory and Formulation Record Through 2026
The U.S. record now includes multiple finished products and application histories. Ozempic injection received original approval under NDA 209637 on December 5, 2017. Rybelsus tablets received original approval under NDA 213051 on September 20, 2019. Wegovy injection received original approval under NDA 215256 on June 4, 2021. Wegovy’s cardiovascular-risk-reduction indication followed on March 8, 2024.
The record expanded again in 2025. FDA added an Ozempic indication addressing kidney-disease progression and cardiovascular death risk in adults with type 2 diabetes and chronic kidney disease on January 28, 2025. On August 15, 2025, FDA granted accelerated approval to a Wegovy injection indication for adults with noncirrhotic MASH and F2 to F3 fibrosis; the required confirmatory trial is scheduled to continue through 2029. FDA then approved Wegovy tablets under NDA 218316 on December 22, 2025.
On March 19, 2026, FDA approved the 7.2 mg Wegovy HD injection presentation for an adult weight-reduction and maintenance indication. This page records that regulatory event without reproducing a prescribing schedule or use instructions. Readers should consult the current FDA label for any approved product because indications, warnings, presentations, and postmarketing requirements can change.
| Record | What it establishes | What it cannot establish |
|---|---|---|
| Ozempic, NDA 209637 | FDA status, labeling, formulation, and approved indications for the named injection product | Status or performance of Rybelsus, Wegovy, a compounded version, or an Apex reagent |
| Rybelsus, NDA 213051 | FDA record for the named oral Semaglutide tablet product | Interchangeability with an injection, Wegovy tablet, or research material |
| Wegovy injection, NDA 215256 | FDA record for the injection product, including later CV and MASH supplements | Automatic transfer of a product-specific indication to Semaglutide as a molecule |
| Wegovy tablets, NDA 218316 | A separate tablet application approved in December 2025 | Equivalence to Rybelsus or an unapproved material merely because all contain Semaglutide |
| Apex material record | Current analyte declaration, lot documentation, and research-use commercial record | FDA approval, an approved indication, clinical safety, efficacy, sterility, or pharmaceutical equivalence |
How to Read Semaglutide Evidence
A useful Semaglutide claim should preserve at least five fields: material or formulation, population or model, comparator, endpoint, and observation period. If any field disappears, the claim becomes easier to misread. “Semaglutide reduced an endpoint” is incomplete; the same sentence should identify whether the record is an in-vitro receptor assay, an animal model, a SUSTAIN injection trial, a PIONEER tablet trial, or a current FDA label.
Formulation deserves special attention. Rybelsus and Wegovy tablets are not the same finished product even though both contain Semaglutide. Ozempic and Wegovy injections have distinct application and labeling records. The MASH indication was granted under accelerated approval and therefore carries a continuing confirmatory-evidence requirement. A clinical result should be cited to the original paper or FDA record, not transferred through a brand-name summary.
For comparisons, use the page that owns the comparison. The binary comparison owns Semaglutide versus Tirzepatide. The three-way GLP-1 agonist guide owns modern class-selection context. This entity guide avoids duplicating their matrices so search engines and readers can identify one clear answer owner for each question.
Semaglutide Research Reagent Versus Pharmaceutical Formulation
The required boundary is explicit: same molecule (semaglutide); categorically distinct regulatory frameworks. Ozempic, Rybelsus, Wegovy injection, Wegovy tablets, and Wegovy HD are FDA-approved finished pharmaceuticals manufactured and labeled under named NDAs. Apex Semaglutide is a chemical research reagent for lawful in-vitro and preclinical work. It is not a pharmaceutical, is not for human or veterinary consumption, and carries no approved indication.
A matching molecular name does not establish matching excipients, formulation, release, container closure, manufacturing controls, sterility, stability, exposure, or clinical performance. Likewise, HPLC and mass spectrometry can support chromatographic profile and mass identity under stated methods, but they do not establish pharmaceutical equivalence. The broader research-grade versus pharmaceutical-grade guide owns this framework.
Current Semaglutide research-material record
The product page can document present availability, analyte labeling, and lot-specific records. It cannot transfer Ozempic, Rybelsus, or Wegovy evidence or FDA status to a research reagent. Recheck the live record before relying on any current specification or availability statement.
Frequently Asked Questions About Semaglutide
What is Semaglutide?
Semaglutide is a 31-residue acylated analog of human GLP-1. Its engineered changes improve DPP-4 stability and support reversible albumin binding while retaining selective GLP-1 receptor agonism.
How does Semaglutide engage the GLP-1 receptor?
Semaglutide selectively binds and activates GLP-1R, a class B G-protein-coupled receptor. In responsive systems, GLP-1R couples primarily through Gs to adenylyl cyclase and cyclic AMP. Downstream findings still depend on the model, tissue, endpoint, comparator, and observation period.
Which structural changes define Semaglutide?
The FDA molecular description identifies a position-8 change that improves DPP-4 stability, a hydrophilic spacer and C18 fatty di-acid attached at lysine 26 that support albumin binding, and a position-34 change that directs a single fatty di-acid attachment.
How are Ozempic, Rybelsus, Wegovy, and Wegovy HD related to Semaglutide?
They are FDA-approved finished pharmaceutical products containing semaglutide. They differ by application record, formulation, presentation, approved indication, manufacturing controls, and labeling. Those product-specific attributes do not transfer to a separate research reagent.
What changed in the U.S. Semaglutide record during 2025 and 2026?
FDA added an Ozempic chronic-kidney-disease indication in January 2025, granted accelerated approval for a Wegovy injection MASH indication in August 2025, approved Wegovy tablets in December 2025, and approved the 7.2 mg Wegovy HD injection presentation in March 2026.
Is the Apex Semaglutide reagent the same as an approved pharmaceutical?
No. The active molecule may be semaglutide, but the Apex material is a chemical research reagent for in-vitro and preclinical work. It is not Ozempic, Rybelsus, Wegovy, or Wegovy HD; it has no FDA-approved indication and is not a therapeutic equivalent.
References and Regulatory Sources
- Lau J, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370-80. PMID: 26308095.
- Knudsen LB, et al. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019;10:155. PMID: 31031702.
- Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-39. PMID: 17928588.
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756. PMID: 29617641.
- Sorli C, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251-260. PMID: 28110911.
- Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. PMID: 27633186.
- Aroda VR, et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019;42(9):1724-1732. PMID: 31186300.
- Husain M, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019;381(9):841-851. PMID: 31185157.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185.
- Davies M, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984. PMID: 33667417.
- Wadden TA, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021;325(14):1403-1413. PMID: 33625476.
- Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. PMID: 33755728.
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131.
- FDA. Ozempic prescribing information. Revised May 2026; molecular description and current product record checked July 24, 2026.
- FDA. Ozempic NDA 209637 original approval letter. December 5, 2017.
- FDA. Rybelsus NDA 213051 approval package. September 20, 2019.
- FDA. Wegovy injection NDA 215256 original approval letter. June 4, 2021.
- FDA. Wegovy cardiovascular-risk-reduction approval package. March 8, 2024.
- FDA. Ozempic NDA 209637/S-025 chronic-kidney-disease indication approval letter. January 28, 2025.
- FDA. Wegovy MASH accelerated-approval letter, NDA 215256/S-024. August 15, 2025.
- FDA. Wegovy tablets NDA 218316 approval letter. December 22, 2025.
- FDA. FDA approval announcement for Wegovy HD. March 19, 2026.
